Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism
- 21 November 2016
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Journal of Bone and Mineral Metabolism
- Vol. 35 (6), 616-622
- https://doi.org/10.1007/s00774-016-0797-0
Abstract
Pharmacological treatment of hypercalcemia is essential for patients with parathyroid carcinoma and intractable primary hyperparathyroidism (PHPT). Use of the calcimimetic cinacalcet hydrochloride (cinacalcet) is an option to treat such patients. We investigated the efficacy and safety of cinacalcet in Japanese patients with parathyroid carcinoma and intractable PHPT. Five Japanese patients with parathyroid carcinoma and two with intractable PHPT were enrolled in an open-label, single-arm study consisting of titration and maintenance phases. Cinacalcet doses were titrated until the albumin-corrected serum calcium concentration decreased to 10.0 mg/dL or less or until dose escalation was considered not necessary or feasible. Serum calcium concentration at the baseline was 12.1 ± 1.3 mg/dL (mean ± standard deviation; range 10.4–14.6 mg/dL) and decreased to 10.1 ± 1.6 mg/dL (range 8.6–13.3 mg/dL) at the end of the titration phase with cinacalcet at a dosage of up to 75 mg three times a day. At the end of the titration phase, at least a 1 mg/dL reduction in serum calcium concentration from the baseline was observed in five patients (three with carcinoma and two with PHPT), and it decreased to the normocalcemic range in five patients (three with carcinoma and two with PHPT). Common adverse events were nausea and vomiting. One patient discontinued participation in the study because of an adverse event, liver disorder. Cinacalcet effectively relieved hypercalcemia in 60% of the Japanese patients with parathyroid carcinoma and might be effective in those with intractable PHPT. The drug might be tolerable and safe at a dosage of at most 75 mg three times a day.Keywords
Funding Information
- Kyowa Hakko Kirin Co., Ltd.
This publication has 16 references indexed in Scilit:
- Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary HyperparathyroidismJournal of Clinical Endocrinology & Metabolism, 2009
- Increased Parathyroid Hormone Gene Expression in Secondary Hyperparathyroidism of Experimental Uremia Is Reversed by CalcimimeticsJournal of the American Society of Nephrology, 2006
- Cinacalcet Hydrochloride Maintains Long-Term Normocalcemia in Patients with Primary HyperparathyroidismJournal of Clinical Endocrinology & Metabolism, 2005
- Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HClThe Journal of pharmacology and experimental therapeutics, 2003
- Medical Management of Primary HyperparathyroidismPublished by Elsevier BV ,2001
- Parathyroid CarcinomaThe American Journal of Surgery, 1998
- Prolonged remission of hypercalcaemia due to parathyroid carcinoma with pamidronatePublished by Oxford University Press (OUP) ,1994
- ORAL BIPHOSPHONATE THERAPY IN METASTATIC PARATHYROID CARCINOMAThe Lancet, 1985
- DISODIUM CLODRONATE EFFECTIVE IN MANAGEMENT OF SEVERE HYPERCALCAEMIA CAUSED BY PARATHYROID CARCINOMAThe Lancet, 1984
- Calcitonin Treatment of Hypercalcemia Due to Parathyroid CarcinomaArchives of Internal Medicine, 1975